glp-1 and dpp4 Inhibitors vs Agonists | June 2021 | Clinical Corner Expert Consensus on Dipeptidyl Peptidase-4
Description
doi: 10.24875/RCCAR.24000056 74 CoxZLCollinsSPHernandezGAMcRaeATDavidsonBTAdamsKet al
After applying the inclusion criteria, eligible respondents with diabetes were divided into two groups: GLP-1 RA users and nonGLP-1 RA users
Patients should have thyroid function monitored during substantial weight loss, with dose adjustments based on TSH and FT4 results
Talk with your doctor about bariatric surgery or GLP-1 medication
